Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2010
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyS J O'Day, M Maio, V Chiarion-Sileni, et al.
British Journal of Cancer|March 13, 2014
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in ItalyV Chiarion-Sileni, J Pigozzo, P A Ascierto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2013
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaM Maio, R Danielli, V Chiarion-Sileni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabP F Ferrucci, P A Ascierto, J Pigozzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre studyG A McArthur, M Maio, A Arance, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2022
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studyM Maio, P A Ascierto, L Manzyuk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)P Saiag, R Gutzmer, P A Ascierto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyA M Di Giacomo, P A Ascierto, P Queirolo, et al.
ESMO Open|August 5, 2021
Skip pattern approach toward the early access of innovative anticancer drugsG Apolone, A Ardizzoni, A Biondi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2023
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1B Besse, E Felip, R Garcia Campelo, et al.
Pageof 9